Investing / Business

Add as a preferred source on Google

S&P 500 Heads for Sixth Straight Loss as AI Shares Reverse Course

The index was down 1.2% intraday after giving up an early gain. Johnson & Johnson named the first hospital for its OTTAVA surgical system and filed to expand CAPLYTA’s uses.

Updated 2 min read
Pedestrians pass the Nasdaq MarketSite in Times Square, New York City, in late afternoon. / TokenPost.ai
Pedestrians pass the Nasdaq MarketSite in Times Square, New York City, in late afternoon. / TokenPost.ai

U.S. stocks reversed early gains on Nov. 19, putting the S&P 500 on course for a sixth consecutive decline as artificial intelligence-linked shares fell after Anthropic began trading on Nasdaq, the Associated Press reported.

The S&P 500 was down 1.2% intraday after rising 1.3% earlier. At 1:43 p.m. ET, the Dow Jones Industrial Average had fallen 755 points, or 1.5%, and the Nasdaq Composite was down 1.3%. About 85% of S&P 500 companies were lower, AP reported. The index’s losing run would be its longest in two and a half years if it closed lower for the session.

Anthropic priced its initial public offering at $83 a share. Its stock briefly rose above $115 before trading at $96.35, up 16%, at the time of AP’s report. AP cited investor concerns about AI valuations and returns, interest rates, possible regulation and a reported resignation by Nvidia CEO Jensen Huang.

Separately, Johnson & Johnson said Memorial Hermann-Texas Medical Center in Houston would be the first hospital to install its OTTAVA robotic surgical system through an early-access commercial program. The Food and Drug Administration (FDA) authorized the system in July for multiple general surgery procedures in the upper abdomen. Johnson & Johnson describes OTTAVA as a surgical-table-integrated system with four robotic arms.

Johnson & Johnson also submitted an application to the FDA seeking approval for CAPLYTA, or lumateperone, to treat manic or mixed episodes associated with bipolar I disorder in adults. The company said both Phase 3 studies showed lower mania symptoms beginning on the third treatment day, with improvement still present at the end of the three-week studies. CAPLYTA is not approved for that use, and the application is pending.

The proposed use would be CAPLYTA’s fifth potential indication for adults. Johnson & Johnson says it is already approved for schizophrenia, depressive episodes associated with bipolar I or II disorder, and as an add-on treatment for major depressive disorder.

Related articles

View all